Just under two weeks ago, Kazia Therapeutics Ltd [ASX:KZA] was making headlines. The company had received ‘the nod’ from the US Food and Drug Administration (FDA) it sorely needed…
Biotech Stocks: Investing in Cutting-Edge Healthcare Innovations
CSL Share Price Spikes Higher on US$2.1 Billion Profit (ASX:CSL)
It seems even a pandemic can’t put a dampener on CSL Ltd’s [ASX:CSL] performance. The biotech superstar has defied all the odds today. Reporting a US$2.1 billion profit for the 2020 financial year. Up 17% from the year prior…
Reality Bites for Cochlear, as Share Price is Buoyed by Hopeful Outlook
Despite this historic loss, the market managed to see the brighter side of things, with shareholders overlooking the recent downturn to see a far more optimistic future. That has helped the COH share price climbed by 9.89% at time of writing — the highest levels it has seen since February….
Earnings Calendar and Why the ASX Is Lagging the US Stock Market
We should see some big moves in individual stocks on the ASX this week. Whether the ASX 200 moves up or down is yet to be seen. A lot of earnings are due and some will surely disappoint…
Mesoblast Share Price Rockets 37% Higher on FDA Vote (ASX:MSB)
It’s been one hell of a roller coaster of emotions for Mesoblast Ltd [ASX:MSB] this week. After the MSB share price experienced a steady rise for much of August, the stock plummeted on Tuesday. Driven lower as news of an upcoming FDA vote was made apparent…
FDA Nod Sends KAZIA Therapeutics Share Price Higher (ASX:KZA)
The share price of oncology-focused biotech firm, KAZIA Therapeutics Ltd [ASX:KZA], soared this morning on the receipt of FDA designation for its brain cancer treatment. At time of writing the KZA share price is up 26 cents or 46.43%, trading at 82 cents per share.
